L-R: Myrobalan Therapeutics' scientific founders Zhigang He and Guoping Feng and co-founder and CEO Jing Wang
January 10, 2024 06:45 AM ESTUpdated 11:59 AM
Financing
Startups
China

CNS biotech My­robal­an Ther­a­peu­tics rais­es $24M Se­ries A to en­ter the clin­ic

Kyle LaHucik

Senior Reporter

My­robal­an Ther­a­peu­tics has raised $24 mil­lion to en­ter the clin­ic with one of its four CNS ther­a­peu­tic can­di­dates, with the goal of ei­ther re­pair­ing or …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times